Published in Health and Medicine Week, May 23rd, 2005
"Recent reports indicate that beta-amyloid peptide (A-beta) vaccine based therapy for Alzheimer disease (AD) may be on the horizon. There are however, concerns about the safety of this approach. Immunization with A-beta has several disadvantages, because it crosses the blood brain barrier and cause inflammation and neurotoxicity. The present work is aimed to study the protective effective of alpha-lipoic acid (LA) in the oxidative vulnerability of beta-amyloid in plasma, liver, spleen and brain, when A-beta fibrils are given intraperitoneally in inflammation...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.